17 July 2007

Evotec Announces the Expansion of its GMP Sterile Pharmaceutical Manufacturing Facility

Hamburg, Germany | Oxford, UK | Glasgow, UK – Evotec AG (Frankfurt Stock Exchange: EVT) announced today the expansion of its sterile pharmaceutical manufacturing facility in Glasgow, Scotland. The Company has doubled its capacity for the aseptic (sterile) GMP manufacture of pharmaceuticals to be used in clinical trials with the new facility being operational with immediate effect.

Evotec’s formulations business is a niche provider of contract pharmaceutical development services for the development of formulations of pharmaceuticals intended for parenteral administration and the manufacture of formulated drugs for use in Phase I and Phase II clinical trials. Its client base comprises pharmaceutical and biotechnology companies around the world and it has particular expertise in the development of lyophilised (freeze-dried) formulations and the subsequent sterile manufacture of those formulated drugs. In addition, it has dedicated facilities to assist in the development of cytotoxic (cytostatic) pharmaceuticals.

The expansion of the facilities is in response to the demand from its clients for clinical supplies of liquid and lyophilised drug product. Evotec has demonstrated its expertise in drug formulation development and sterile manufacturing, offering its clients services of the highest quality and technical standards. These additional facilities will allow Evotec to shorten the lead-time to access its manufacturing capabilities and will save its clients time. This will therefore accelerate the progression of Evotec’s clients’ drugs into the clinical stage of drug development.

About Evotec AG

Evotec is a leader in the discovery and development of novel small molecule drugs. Both through its own discovery programmes and through research collaborations, the Company is generating the highest quality research results to its partners in the pharmaceutical and biotechnology industries.

In proprietary projects, Evotec specialises in finding new treatments for diseases of the Central Nervous System. Evotec has three programmes in clinical development: EVT 201, a partial positive allosteric modulator (pPAM) of the GABA A receptor complex for the treatment of insomnia, EVT 101, a subtype selective NMDA receptor antagonist for the treatment of Alzheimer’s disease and/or pain, and EVT 302, a MAO-B inhibitor in development for smoking cessation.

In research collaborations, Evotec has established itself as the partner of choice for pharmaceutical and biotechnology companies worldwide. The Company provides innovative and often integrated solutions from drug target to clinic through an unmatched range of capabilities, including early stage assay development and screening through to medicinal chemistry and drug manufacturing.

www.evotec.com